Novocure Shares Rise After Co Boosts FY26 Revenue Guidance

Dow Jones

07/23

Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter.

The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year.

Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier.

Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million.

Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability.

Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million.

Write to Grace Yoon at grace.yoon@wsj.com

(END) Dow Jones Newswires

July 23, 2026 10:03 ET (14:03 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2653725705"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653725705\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653725705?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653725705","market":"sh","top_or_hot":-1,"title":"Novocure Shares Rise After Co Boosts FY26 Revenue Guidance","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter. \n</p>\n<p>\n  The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year. \n</p>\n<p>\n  Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier. \n</p>\n<p>\n  Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million. \n</p>\n<p>\n  Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability. \n</p>\n<p>\n  Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 10:03 ET (14:03 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure Shares Rise After Co Boosts FY26 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure Shares Rise After Co Boosts FY26 Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-23 22:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter. \n</p>\n<p>\n  The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year. \n</p>\n<p>\n  Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier. \n</p>\n<p>\n  Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million. \n</p>\n<p>\n  Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability. \n</p>\n<p>\n  Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 10:03 ET (14:03 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653725705","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653725705","pubTimestamp":1784815380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter.The stock was up 26% to $19.59 in recent tr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","NVCR":"NovoCure Limited","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","BK4082":"医疗保健设备"},"translate_title":"公司上调 26 财年收入指引后，Novocure 股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":0.9},"content_text":"Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter. \n\n\n  The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year. \n\n\n  Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier. \n\n\n  Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million. \n\n\n  Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability. \n\n\n  Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million. \n\n\n \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 23, 2026 10:03 ET (14:03 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}